AI English summary of an SEC filing — figures as filed
Intuitive Surgical ISRGThe company said preliminary revenue for Q4 2023 was approximately $1.93 billion, up 17% from $1.66 billion in Q4 2022. It said preliminary revenue for the full year 2023 was approximately $7.12 billion, up 14% from $6.22 billion in 2022.
Key points
AI summaryThe company said preliminary revenue for Q4 2023 was approximately $1.93 billion, up 17% from $1.66 billion in Q4 2022. It said preliminary revenue for the full year 2023 was approximately $7.12 billion, up 14% from $6.22 billion in 2022.
The company said worldwide da Vinci procedures for the full year 2023 rose about 22%, from approximately 1,875,000 in 2022 to approximately 2,286,000. It also said it expects worldwide da Vinci procedures to increase 13% to 16% in 2024 compared with 2023.
The company said preliminary instruments and accessories revenue for Q4 2023 rose 22% to approximately $1.14 billion ($0.94 billion in the same period a year earlier), and full-year revenue rose 22% to approximately $4.28 billion ($3.52 billion in 2022). It cited higher procedure volume and higher pricing as the main drivers, and said customer buying patterns partially offset them.
The company said it placed 1,370 da Vinci surgical systems in 2023, up 8% from 1,264 in 2022, and that 659 of them were placed under operating lease arrangements, including 355 under usage-based operating lease arrangements. It placed 415 systems in Q4, of which 201 were placed under operating lease arrangements and 109 under usage-based operating lease arrangements.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 2023 and Full-Year Preliminary Revenue
The company said preliminary revenue for Q4 2023 was approximately $1.93 billion, up 17% from $1.66 billion in Q4 2022. It said preliminary revenue for the full year 2023 was approximately $7.12 billion, up 14% from $6.22 billion in 2022.
Source · Based on the filing body and exhibits
da Vinci Procedure Growth and 2024 Outlook
The company said worldwide da Vinci procedures for the full year 2023 rose about 22%, from approximately 1,875,000 in 2022 to approximately 2,286,000. It also said it expects worldwide da Vinci procedures to increase 13% to 16% in 2024 compared with 2023.
Source · Based on the filing body and exhibits
Instruments and Accessories Revenue and Company Explanation
The company said preliminary instruments and accessories revenue for Q4 2023 rose 22% to approximately $1.14 billion ($0.94 billion in the same period a year earlier), and full-year revenue rose 22% to approximately $4.28 billion ($3.52 billion in 2022). It cited higher procedure volume and higher pricing as the main drivers, and said customer buying patterns partially offset them.
Source · Based on the filing body and exhibits
da Vinci System Placements and Operating Leases
The company said it placed 1,370 da Vinci surgical systems in 2023, up 8% from 1,264 in 2022, and that 659 of them were placed under operating lease arrangements, including 355 under usage-based operating lease arrangements. It placed 415 systems in Q4, of which 201 were placed under operating lease arrangements and 109 under usage-based operating lease arrangements.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…